Daymark Wealth Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Daymark Wealth Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.27M	Hold	17,750	–	–	0.07%	193
2025 Q4	$2.16M	Hold	17,750	–	–	0.07%	186
2025 Q3	$1.78M	Hold	17,750	–	–	0.06%	207
2025 Q2	$1.47M	Hold	17,750	–	–	0.06%	213
2025 Q1	$1.44M	Hold	17,750	–	–	0.06%	199
2024 Q4	$1.6M	Hold	17,750	–	–	0.07%	186
2024 Q3	$1.75M	Buy	17,750 +150	+0.9%	+$14.7K	0.07%	181
2024 Q2	$1.63M	Sell	17,600 -750	-4%	-$67.2K	0.07%	178
2024 Q1	$1.74M	Hold	18,350	–	–	0.09%	140
2023 Q4	$1.64M	Hold	18,350	–	–	0.1%	140
2023 Q3	$1.34M	Buy	18,350 +2,475	+16%	+$198K	0.09%	147
2023 Q2	$1.32M	Buy	+15,875	New	+$1.33M	0.1%	147

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Daymark Wealth Partners's XBI Position: Q1 2026 in Review

Daymark Wealth Partners held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 17,750 shares worth $2.27M. The position accounts for 0.07% of the portfolio, ranked #193.

Daymark Wealth Partners first reported a position in XBI in Q2 2023 and has held it in 12 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Daymark Wealth Partners held 17,750 shares of State Street SPDR S&P Biotech ETF worth $2.27M as of Q1 2026.
Daymark Wealth Partners left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.07% of Daymark Wealth Partners's portfolio in Q1 2026, its #193 holding.
Daymark Wealth Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and has held it in 12 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Daymark Wealth Partners's 13F filing for Q1 2026, filed 11 May 2026.